These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 38359439)

  • 1. Advances in targeted therapy of cholangiocarcinoma.
    Li Y; Yu J; Zhang Y; Peng C; Song Y; Liu S
    Ann Med; 2024 Dec; 56(1):2310196. PubMed ID: 38359439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Micro-RNA-130a-3p Regulates Gemcitabine Resistance via PPARG in Cholangiocarcinoma.
    Asukai K; Kawamoto K; Eguchi H; Konno M; Asai A; Iwagami Y; Yamada D; Asaoka T; Noda T; Wada H; Gotoh K; Nishida N; Satoh T; Doki Y; Mori M; Ishii H
    Ann Surg Oncol; 2017 Aug; 24(8):2344-2352. PubMed ID: 28560603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case report: A report of the complete pathological response of intrahepatic cholangiocarcinoma after conversion therapy.
    Zhang X; Tang H; Fan J; Wang R; Han Y; Su S; Gan Y; Peng F; Rao M; Zhang J; Li B; Yang X
    Front Immunol; 2022; 13():1051130. PubMed ID: 36618353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Future directions in the treatment of cholangiocarcinoma.
    Zhu AX
    Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):355-61. PubMed ID: 25966434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholangiocellular Carcinoma.
    Vogel A; Saborowski A
    Digestion; 2017; 95(3):181-185. PubMed ID: 28288474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic therapy of cholangiocarcinoma: From chemotherapy to targeted therapies.
    Schweitzer N; Vogel A
    Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):345-53. PubMed ID: 25966433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Revisiting targeted therapy and immunotherapy for advanced cholangiocarcinoma.
    Du J; Lv X; Zhang Z; Huang Z; Zhang E
    Front Immunol; 2023; 14():1142690. PubMed ID: 36936931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in research and application of photodynamic therapy in cholangiocarcinoma (Review).
    Li Y; Li Y; Song Y; Liu S
    Oncol Rep; 2024 Mar; 51(3):. PubMed ID: 38334150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential targeted therapy for liver fluke associated cholangiocarcinoma.
    Vaeteewoottacharn K; Seubwai W; Bhudhisawasdi V; Okada S; Wongkham S
    J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):362-70. PubMed ID: 24408866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in pharmacotherapy for cholangiocarcinoma: from conventional therapies to targeted drugs.
    Spolverato G; Glavas D; Hewitt DB; Brown ZJ; Capelli G; Bergamo F; Rizzato MD; Pawlik TM
    Expert Opin Pharmacother; 2022 Mar; 23(4):473-481. PubMed ID: 34964678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
    Sahai V; Catalano PJ; Zalupski MM; Lubner SJ; Menge MR; Nimeiri HS; Munshi HG; Benson AB; O'Dwyer PJ
    JAMA Oncol; 2018 Dec; 4(12):1707-1712. PubMed ID: 30178032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Photochemical Internalization of Gemcitabine Is Safe and Effective in Locally Advanced Inoperable Cholangiocarcinoma.
    Trojan J; Hoffmeister A; Neu B; Kasper S; Dechêne A; Jürgensen C; Schirra J; Jakobs R; Palmer D; Selbo PK; Olivecrona H; Finnesand L; Høgset A; Walday P; Sturgess R
    Oncologist; 2022 Jun; 27(6):430-e433. PubMed ID: 35675633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MET‑RON dual inhibitor, BMS‑777607, suppresses cholangiocarcinoma cell growth, and MET‑RON upregulation indicates worse prognosis for intra‑hepatic cholangiocarcinoma patients.
    Cheng CT; Chen YY; Wu RC; Tsai CY; Chiang KC; Yeh TS; Chen MH; Yeh CN
    Oncol Rep; 2018 Sep; 40(3):1411-1421. PubMed ID: 30015968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic Phenotyping Predicts Gemcitabine and Cisplatin Chemosensitivity in Patients With Cholangiocarcinoma.
    Suksawat M; Phetcharaburanin J; Klanrit P; Namwat N; Khuntikeo N; Titapun A; Jarearnrat A; Vilayhong V; Sa-Ngiamwibool P; Techasen A; Wangwiwatsin A; Mahalapbutr P; Li JV; Loilome W
    Front Public Health; 2022; 10():766023. PubMed ID: 35223723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Factors for Survival in Patients with Advanced Intrahepatic Cholangiocarcinoma Treated with Gemcitabine plus Cisplatin as First-Line Treatment.
    Ishimoto U; Kondo S; Ohba A; Sasaki M; Sakamoto Y; Morizane C; Ueno H; Okusaka T
    Oncology; 2018; 94(2):72-78. PubMed ID: 29017161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatments, prognostic factors, and genetic heterogeneity in advanced cholangiocarcinoma: A multicenter real-world study.
    Ottaiano A; Santorsola M; Diana A; Belli A; Lentini Graziano ML; Orefice J; Patrone R; Di Mauro A; Scognamiglio G; Tatangelo F; De Bellis M; Piccirillo M; Fiore F; Stilo S; Tarotto L; Correra M; Di Lorenzo S; Capuozzo M; Avallone A; Silvestro L; Bianco A; Granata V; Federico P; Montesarchio V; Daniele B; Izzo F; Nasti G
    Cancer Med; 2024 Feb; 13(4):e6892. PubMed ID: 38457226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase II Study of Nab-Paclitaxel and Gemcitabine as First-Line Therapy in Patients with Cholangiocarcinoma Ineligible for Cisplatin-Based Chemotherapy (NACHO).
    Virchow I; Treckmann JW; Prasnikar N; Linden G; Markus P; Schumacher B; Albers D; Herold T; Ting S; Schmidt H; Radunz S; Wiesweg M; Siveke J; Schuler M; Kasper S
    Oncol Res Treat; 2023; 46(3):89-99. PubMed ID: 36623497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delayed response to maintenance therapy after first-line chemotherapy in metastatic intrahepatic cholangiocarcinoma: a case report.
    Marciano R; Servetto A; Bianco C; Bianco R
    J Med Case Rep; 2017 Sep; 11(1):273. PubMed ID: 28946921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular pathways and targeted therapy in cholangiocarcinoma.
    Dabney RS; Khalife M; Shahid K; Phan AT
    Clin Adv Hematol Oncol; 2019 Nov; 17(11):630-637. PubMed ID: 31851165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholangiocarcinoma Therapeutics: An Update.
    Nguyen MLT; Toan NL; Bozko M; Bui KC; Bozko P
    Curr Cancer Drug Targets; 2021; 21(6):457-475. PubMed ID: 33563168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.